about
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementOptimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agentsUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelinePhase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsActivation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscapeEvaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure.Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives.Evaluating beauty care provided by the hospital to women suffering from breast cancer: qualitative aspects.Genomic index of sensitivity to endocrine therapy for breast cancer.A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.Rationale for targeting fibroblast growth factor receptor signaling in breast cancerEstrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in EuropeA network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypesPrognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy.Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factorsMolecular classification of breast cancer: implications for selection of adjuvant chemotherapy.Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology.DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trialA Systematic Evaluation of Blood Serum and Plasma Pre-Analytics for Metabolomics Cohort Studies.Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter studyPhase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.Issues in clinical research for metastatic breast cancer.Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
P50
Q27020973-7E40911A-20E8-4AA2-B106-8E9447248B20Q27027060-ACAC8D18-53A1-4BEA-A906-9B3970952A58Q28079118-FB382C43-8737-4240-89C5-D2D87F58E127Q28247372-59791D1A-1570-437A-913E-D1EA754851D9Q29615665-D09CACCB-CC5C-49C5-B435-7F856FBE8585Q30313649-10E9B8FB-7DC4-4E4E-8726-CCA60A9CCC99Q30317067-D74B81CE-393A-4917-AEA5-0E566C0ADCCAQ30857631-8D541BE5-936B-4AC5-99D6-D15ABF45A2C5Q31060070-FFB1D614-BC5D-4F53-B2B3-BB4E9497FF71Q33608185-F56D4D37-8C27-42BB-A62F-783D9D2229FAQ33688307-FA1E4FC1-9CAD-4AC1-A56E-4D0BD3DCA227Q33738675-2FC77347-F8E9-48EC-9D57-FD213D7ED628Q34017258-5BD2A8BB-D6DB-4D59-A655-C4D8A84AF30AQ34193932-C79510ED-ADD2-4130-8918-B7E11F3AAF26Q35033439-6EBCD9B4-35A9-4E67-92BD-24371DE83286Q35131258-05928A15-B5D5-45F7-8A52-DA931300A210Q35584058-7521F6BF-0D6C-412A-8CCE-5D7393274D05Q35820168-A82976CC-73DE-4A2F-8822-BCEB37CDABE0Q35832269-4A744783-EFBD-4623-B0AA-563F95B30D9EQ35879081-969AD62A-D446-4F22-A66A-B869D3742F87Q36233937-8A4E444C-A50B-48A2-8CAA-ED7A33899333Q36449290-C6F50149-EC93-4845-AB41-1DCA34BED716Q36564872-312BEEEF-9B05-440C-A76B-F75A562ECB96Q36622856-8D10F33A-2901-44B9-8F17-23AB0DD305D3Q36642141-0EAC8A59-332C-461A-BA61-78A556E613F0Q36755089-46A2CC41-A05A-4A57-8C6D-25E51EAE2347Q37100056-C57799A0-8471-4ACB-8014-440C31B70DB3Q37247163-B35C43C0-2607-4351-A9B6-875AE584E1ACQ37347500-163287D9-7599-49E9-B7B8-A49A62ECEB6BQ37534669-522A00C9-92BF-47F3-B228-9FD617157CE7Q37600494-45B812A2-F008-48CF-BE94-5C9D196AED16Q37635256-CEEB4DAE-F649-4508-B6AB-77C458BE07ADQ38007148-F8BD2553-C6E0-464C-A963-06DFF864A7D8Q38042235-7F8D4BD5-CCFC-41A2-A040-672BCC0D64B4Q38061108-2F433348-237C-4A87-BE02-F4A4414DC29AQ38069133-D123A750-9FF7-42B9-9AD5-783193FD1EA7Q38149797-35FC4489-AB61-4E0C-8721-1FA958722905Q38149798-F527515B-CE64-47D0-B05B-99D09B178767Q38199328-F1D35252-022B-4DE2-B777-6659ABDE48FDQ38302227-1D9410DD-9A8C-4FF5-A087-60B743D06238
P50
description
researcher
@en
wetenschapper
@nl
name
F Andre
@en
F Andre
@nl
type
label
F Andre
@en
F Andre
@nl
prefLabel
F Andre
@en
F Andre
@nl
P106
P31
P496
0000-0001-5795-8357